HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.

Abstract
In recent years many risk factors for the development of breast cancer that are linked to estrogens have been identified, and roscovitine (ROSC), a selective cyclin-dependent kinase (CDK) inhibitor, has been shown to be an efficient inhibitor of the proliferation of human breast cancer cells. Therefore, we have examined the possibility that interference with estrogen signaling pathways, using tamoxifen (TAM), a selective estrogen receptor modulator (SERM), could modulate the efficacy of treatment with ROSC. In conjunction with TAM, ROSC exhibited enhanced anti-proliferative activity and CDK inhibition, particularly in estrogen-dependent MCF-7 cells. The interaction between both drugs was synergistic. However, in ER-α-negative cells the interaction was antagonistic. Exposure of MCF-7 cells to ROSC abolished the activating phosphorylation of CDK2 and CDK7 at Ser(164/170). This in turn prevented the phosphorylation of the carboxyl-terminal repeat domain of RNA Polymerase II and ER-α at Ser(118), resulting in the down-regulation of the latter. Concomitantly, wt p53 was strongly activated by phosphorylation at Ser(46). Our results demonstrate that ROSC negatively affects the functional status of ER-α, making it potentially useful in the treatment of estrogen-dependent breast cancer cells.
AuthorsJózefa Węsierska-Gądek, David Gritsch, Nora Zulehner, Oxana Komina, Margarita Maurer
JournalJournal of cellular biochemistry (J Cell Biochem) Vol. 112 Issue 4 Pg. 1103-17 (Apr 2011) ISSN: 1097-4644 [Electronic] United States
PMID21308739 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 Wiley-Liss, Inc.
Chemical References
  • Estrogen Receptor alpha
  • Protein Kinase Inhibitors
  • Purines
  • Selective Estrogen Receptor Modulators
  • Tamoxifen
  • Roscovitine
  • Serine
  • CDK2 protein, human
  • Cyclin-Dependent Kinase 2
  • Cyclin-Dependent Kinases
  • Cyclin-Dependent Kinase-Activating Kinase
  • CDK7 protein, human
Topics
  • Breast Neoplasms (metabolism, pathology)
  • Cell Cycle (drug effects)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cyclin-Dependent Kinase 2 (antagonists & inhibitors, metabolism)
  • Cyclin-Dependent Kinases (antagonists & inhibitors, metabolism)
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Estrogen Receptor alpha (metabolism)
  • Flow Cytometry
  • G2 Phase (drug effects)
  • HeLa Cells
  • Humans
  • Immunoblotting
  • Membrane Potential, Mitochondrial (drug effects)
  • Phosphorylation (drug effects)
  • Protein Kinase Inhibitors (pharmacology)
  • Purines (pharmacology)
  • Roscovitine
  • Selective Estrogen Receptor Modulators (pharmacology)
  • Serine (metabolism)
  • Tamoxifen (pharmacology)
  • Time Factors
  • Cyclin-Dependent Kinase-Activating Kinase

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: